Stoke Therapeutics Inc. (STOK)
29.81
-0.18 (0.60%)
Upcoming Events
Latest Headlines
Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
September 4, 2026 6:00 AM - StreetInsider
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
September 3, 2026 7:30 PM - StreetInsider
Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
September 1, 2026 7:30 AM - StreetInsider
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
September 1, 2026 7:30 AM - StreetInsider
JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight
August 21, 2026 3:28 AM - StreetInsider
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry
August 18, 2026 8:30 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD
August 18, 2026 8:29 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan
August 18, 2026 8:27 PM - SEC Filing
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 18, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK
August 12, 2026 4:10 PM - SEC Filing
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: FMR LLC
August 6, 2026 10:42 AM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 03 Filed by: Ticho Barry
August 5, 2026 4:22 PM - SEC Filing
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026 8:00 AM - BizWire
Stoke Therapeutics (STOK) PT Lowered to $58 at Canaccord
August 4, 2026 6:44 AM - StreetInsider
Form 8-K Stoke Therapeutics, Inc. For: Aug 03
August 3, 2026 5:06 PM - SEC Filing
Form 424B5 Stoke Therapeutics, Inc.
August 3, 2026 5:04 PM - SEC Filing
Form 144 Stoke Therapeutics, Inc. Filed by: Ticho Barry
August 3, 2026 4:49 PM - SEC Filing
Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 16c
August 3, 2026 4:41 PM - StreetInsider
Form S-8 Stoke Therapeutics, Inc.
August 3, 2026 4:40 PM - SEC Filing
Form 10-Q Stoke Therapeutics, Inc. For: Jun 30
August 3, 2026 4:08 PM - SEC Filing
Form 8-K Stoke Therapeutics, Inc. For: Aug 03
August 3, 2026 4:06 PM - SEC Filing
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
August 3, 2026 4:01 PM - BizWire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
July 27, 2026 4:01 PM - BizWire
Form 4 Stoke Therapeutics, Inc. For: Jul 16 Filed by: Harrison Seth Loring
July 17, 2026 4:37 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Jul 15 Filed by: McCauley Thomas
July 17, 2026 4:36 PM - SEC Filing
Form 3 Stoke Therapeutics, Inc. For: Jul 13 Filed by: McCauley Thomas
July 17, 2026 4:33 PM - SEC Filing
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2026 4:01 PM - BizWire
Stoke Therapeutics names Thomas McCauley as chief scientific officer
July 13, 2026 7:30 AM - StreetInsider
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026 7:30 AM - BizWire
Goldman Sachs Starts Stoke Therapeutics (STOK) at Buy
July 13, 2026 5:10 AM - StreetInsider
Form 4 Stoke Therapeutics, Inc. For: Jul 01 Filed by: Ticho Barry
July 6, 2026 4:11 PM - SEC Filing
Form 144 Stoke Therapeutics, Inc. Filed by: Ticho Barry
July 1, 2026 4:52 PM - SEC Filing
Form 8-K Stoke Therapeutics, Inc. For: Jun 30
June 30, 2026 8:02 AM - SEC Filing
Stoke Therapeutics completes enrollment in Phase 3 Dravet study
June 30, 2026 8:01 AM - StreetInsider
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
June 30, 2026 8:00 AM - BizWire
Form 4 Stoke Therapeutics, Inc. For: Jun 16 Filed by: Allan Jonathan
June 18, 2026 4:19 PM - SEC Filing
Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan
June 16, 2026 4:34 PM - SEC Filing
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2026 4:01 PM - BizWire
Full Article List
